Testosterone and cardiovascular disease – the controversy and the facts

References

• Aub J. Endocrines: the use of testosterone. N Engl J Med 1940;222:877–81
   Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7
   Google Scholar
• Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465–6
   PubMed Web of Science ®Google Scholar
• Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115–23
   PubMed Web of Science ®Google Scholar
• Available from http://www.nytimes.com/2014/02/05/opinion/overselling-testosterone-dangerously.html?_r=0
   Google Scholar
• Vigen R, O’Donnell CI, Barón AE, et al. Testosterone therapy following coronary angiography associated with increased risk of adverse outcomes. JAMA 2013;310:1829–36
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male 2014;17:63–5
   PubMed Web of Science ®Google Scholar
• Finkle WD, Sander Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Published PLoS One.January 29 2014. Available from http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.008580
   Google Scholar
• Morgentaler A. Testosterone, cardiovascular risk, and hormonophobia. J Sex Med 2014;1362–6
   PubMedGoogle Scholar
• NIH heart attack calculator. Available from http://cvdrisk.nhlbi.nih.gov/calculator.asp
   Google Scholar
• Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–22
   PubMed Web of Science ®Google Scholar
• Lin JW, Lee JK, Wu CK, et al. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011;8:2350–60
   PubMedGoogle Scholar
• Carson CCIII, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2011;9:54–67
   PubMedGoogle Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011;34:1669–75
   PubMed Web of Science ®Google Scholar
• Svartberg J, von Muhlen D, Schimer H, Barrett-Coner E, Sandfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol 2004;140:65–71
   Google Scholar
• Araujo AB, Dixon JM, Suarez EA, Hassan Murad M, Guey LT, Wittert GA. Clinical review; Endogenous testosterone and mortality in men; a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007–19
   PubMed Web of Science ®Google Scholar
• Wehr E, Pilz S, Boehm BO, Grammer TB, Marz W, Obermayer-Pietsch B. Low free testosterone levels are associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011;13:482–8
   PubMedGoogle Scholar
• Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494–501
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkend E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men; European prospective investigation in cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694–701
   PubMed Web of Science ®Google Scholar
• Kay-Khaw T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. Circulation 2007;116:2694–701
   PubMedGoogle Scholar
• Saad F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev 2012;28:52–9
   PubMedGoogle Scholar
• Pugh PJ, Jones RD, Jones TH, et al. Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail 2002;4:673–80
   PubMedGoogle Scholar
• Kaplan SA, Johnson-Levonas AO, Lin J, Shah AK, Meehan AG. Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Aging Male 2010;13:108–12
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J, et al. Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women. N Engl J Med 2004;351:2599–610
   PubMed Web of Science ®Google Scholar
• Li ZB, Wang J, Wang JX, Chen XM, Jiang SS. Testosterone therapy improves cardiac function of male rats with right heart failure. Natl J Androl 2009;15:994–1000
   Google Scholar
• Saad F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev 2012;28:S52–9
   PubMedGoogle Scholar
• Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ, Celermajer DS. Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf) 2003;59:62–7
   PubMed Web of Science ®Google Scholar
• Park BJ, Shim JY, Lee YJ, Lee JH, Lee HR. Inverse relationship between bioavailable testosterone and subclinical coronary artery calcification in non-obese Korean men. Asian J Androl 2012;14:612–15
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305–8
   PubMed Web of Science ®Google Scholar
• Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008;29:534–9
   PubMedGoogle Scholar
• D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction. J Clin Oncol 2007;25:2420–5
   PubMed Web of Science ®Google Scholar
• Haidar A, Yassin A, Saad F, Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 2007;10:189–96
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011;25:337–53
   PubMed Web of Science ®Google Scholar
• Svartberg J, Agledahl I, Figenschau Y, Aildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20:378–87
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LGG, Giltray EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome; the double-blinded placebo-controlled Moscow study. Clin Endocrinol(Oxf) 2010;73:602–12
   PubMed Web of Science ®Google Scholar
• Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhövel F, et al. More than eight years’ hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007;9:291–7
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:2074–9
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, Saad F, Nieschlag E. Testosterone administration decreases carotid artery intima media thickness as indicator of vascular damage in middle-aged overweight men. J Androl 2008;54–5
   Google Scholar
• Avers A, Bruzziches R, Rancomano D, et al. Effects of testosterone undeconate on cardiovascular risk factors and atherosclerosis in middle aged men with late-onset hypogonadism and metabolic syndrome; results from a 24-month randomized double-blind, placebo-controlled study. J Sex Med 2010;7:3495–503
   PubMedGoogle Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899–906
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;1636–42
   PubMedGoogle Scholar
• Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2010;34:528–40
   PubMedGoogle Scholar
• Grossmann M, Gianatti E, Zajac J. Testosterone and type 2. Curr Opin Endocrinol Diabetes Obes 2010;17:247–56
   PubMedGoogle Scholar
• English KM, Steeds RP, Jones HT, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906–11
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and mood. Heart 2004;90:871–6
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Behre HM, Bouchard P, Corrales Jones TH, Stalla GK, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004;10:409–19
   PubMed Web of Science ®Google Scholar
• Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med 2011;124:578–87
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014;68:314–29
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? OJM 2013;96:521–9
   Google Scholar
• Wu MD, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123–35
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482–92
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes:an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995–2010
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A Synthesis of international expert opinions. J Sex Med 2014;11:1636–45
   PubMed Web of Science ®Google Scholar
• Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med 2011;124:578–87
   PubMed Web of Science ®Google Scholar
• Kim YC, Buvat J, Carson CCC, Gooren LJ, Jarow J, Rajfer J, et al. Endocrine and metabolic aspect including treatment. Committee 7
   Google Scholar
• Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R. editors. Proceedings of the first international consultation on erectile dysfunction. Health Publication Ltd; Plymouth: 2000. p 204–40
   Google Scholar
• Khera M, Lipshultz L. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin N Am 2007;34:549–53
   PubMed Web of Science ®Google Scholar
• Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639–50
   PubMed Web of Science ®Google Scholar
• Kim YC. Hormonal replacement therapy and aging: Asian practical recommendations on testosterone supplementation. Asian J Androl 2003;5:339–44
   PubMedGoogle Scholar
• Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging 2007;2:577–90
   PubMed Web of Science ®Google Scholar
• O’Hanlon LA. FDA declines approval of testosterone drug for third time. Lancet Diabetes Endocrinol 2013;1:14
   PubMedGoogle Scholar
• McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel®) insertion. J Sex Med 2012;9:594–601
   PubMed Web of Science ®Google Scholar
• Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in Man. J Clin Endocrinolo Metab 1990;71:216–22
   PubMed Web of Science ®Google Scholar